CN121311472A - 化合物或其盐及其制造方法、组合物、过氧化氢清除剂以及细胞毒性抑制剂 - Google Patents
化合物或其盐及其制造方法、组合物、过氧化氢清除剂以及细胞毒性抑制剂Info
- Publication number
- CN121311472A CN121311472A CN202480039105.XA CN202480039105A CN121311472A CN 121311472 A CN121311472 A CN 121311472A CN 202480039105 A CN202480039105 A CN 202480039105A CN 121311472 A CN121311472 A CN 121311472A
- Authority
- CN
- China
- Prior art keywords
- mass
- less
- hydrogen peroxide
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098209 | 2023-06-15 | ||
| JP2023-098209 | 2023-06-15 | ||
| PCT/JP2024/021265 WO2024257775A1 (ja) | 2023-06-15 | 2024-06-12 | 化合物又はその塩及びその製造方法、組成物、過酸化水素除去剤、並びに、細胞毒性抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN121311472A true CN121311472A (zh) | 2026-01-09 |
Family
ID=93852144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202480039105.XA Pending CN121311472A (zh) | 2023-06-15 | 2024-06-12 | 化合物或其盐及其制造方法、组合物、过氧化氢清除剂以及细胞毒性抑制剂 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4729511A1 (https=) |
| JP (1) | JP7755772B2 (https=) |
| KR (1) | KR20260022421A (https=) |
| CN (1) | CN121311472A (https=) |
| WO (1) | WO2024257775A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007300916A (ja) * | 2006-04-10 | 2007-11-22 | Manabu Nukina | エルゴチオネインの製造方法 |
| JP2008156320A (ja) | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
| CN109091422B (zh) | 2018-08-01 | 2021-06-04 | 上海应用技术大学 | 含榆黄菇提取液的化妆品及其制备方法 |
| CN109293572A (zh) | 2018-09-26 | 2019-02-01 | 上海市农业科学院 | 一种提取榆黄菇中麦角硫因与多糖的方法 |
| JP2020103100A (ja) | 2018-12-27 | 2020-07-09 | 小林製薬株式会社 | 細胞内の抗酸化機能亢進剤 |
| JP6864131B1 (ja) | 2020-03-04 | 2021-04-28 | 長瀬産業株式会社 | Ｌ−エルゴチオネイン含有組成物 |
-
2024
- 2024-06-12 CN CN202480039105.XA patent/CN121311472A/zh active Pending
- 2024-06-12 JP JP2025519185A patent/JP7755772B2/ja active Active
- 2024-06-12 KR KR1020267000808A patent/KR20260022421A/ko active Pending
- 2024-06-12 EP EP24823390.0A patent/EP4729511A1/en active Pending
- 2024-06-12 WO PCT/JP2024/021265 patent/WO2024257775A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP7755772B2 (ja) | 2025-10-16 |
| WO2024257775A1 (ja) | 2024-12-19 |
| EP4729511A1 (en) | 2026-04-22 |
| JPWO2024257775A1 (https=) | 2024-12-19 |
| KR20260022421A (ko) | 2026-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230107256A1 (en) | Quinoline derived small molecule inhibitors of nicotinamide n-methyltransferase (nnmt) and uses thereof | |
| Zimmermann et al. | Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei | |
| EP3199158B1 (en) | Oxazolidin-2-one-pyrimidine derivatives for use in the treatment of skin fibrosis, scleroderma, hypertrophic scars or keloids | |
| EP3277675B1 (en) | Heterocyclic modulators of lipid synthesis | |
| CN112367991A (zh) | Taire家族激酶抑制剂及其用途 | |
| CN108467385A (zh) | 一种氘代奥斯替尼衍生物及其应用 | |
| JP2020503280A (ja) | ヒドロキシ安息香酸誘導体、その方法および使用 | |
| Arsenyan et al. | 4-Methyl-1, 2, 3-selenadiazole-5-carboxylic acid amides: antitumor action and cytotoxic effect correlation | |
| Ramachandran et al. | Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors | |
| Fantacuzzi et al. | Screening of NOS activity and selectivity of newly synthesized acetamidines using RP-HPLC | |
| Cort et al. | Bleomycin-induced trans lipid formation in cell membranes and in liposome models | |
| CN121311472A (zh) | 化合物或其盐及其制造方法、组合物、过氧化氢清除剂以及细胞毒性抑制剂 | |
| Guiotto et al. | Malondialdehyde scavenging and aldose-derived Schiff bases’ transglycation properties of synthetic histidyl-hydrazide carnosine analogs | |
| Ruggenthaler et al. | Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis | |
| FR2984317A1 (fr) | Composes chelateurs de metal presentant au moins une chaine polyaminee. | |
| WO2020210662A1 (en) | Small molecules for cancer therapy that reduce the expression of transcription factors klf5 and egr-1 | |
| Zaher et al. | LC–MS metabolite fingerprinting and MtSK-based screening of an endophyte Bartalinia pondoensis Marinc of Citrus aurantum L | |
| Absi et al. | Decrease of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline synthesizing enzyme activity in the brain areas of aged rat | |
| WO2023081725A1 (en) | Uses of rhodoquinone for the treatment of disease | |
| CN119751452B (zh) | 新型fsp1降解剂protac类化合物及其制备方法和应用 | |
| McDonnell et al. | De-novo designed β-lysine derivatives can both augment and diminish the proliferation rates of E. coli through the action of Elongation Factor P | |
| WO2025165846A1 (en) | Rhodoquinone mimetics and methods of making and using thereof | |
| KR102926914B1 (ko) | 신규한 타이로신 유도체 | |
| JP2015514728A (ja) | Ｋｃｎｑ２／３調節因子としてのｏｈ含有基を有する置換６−アミノ−ニコチンアミド類 | |
| Ram Reddy et al. | Separation, identification and structural elucidation of a new impurity in the drug substance of amlodipine maleate using LC-MS/MS, NMR and IR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |